We propose that presence of a strong KIR3DL1+–Bw4 interaction improves NK cell education and thus is advantageous in AML patients receiving HDC/IL-2 immunotherapy for relapse prevention. The gene discussed is KIR3DL1; the disease is acute myeloid leukemia.